37 results
PRE 14A
ONCR
Oncorus, Inc.
12 Jun 23
Preliminary proxy
6:33am
product pipeline to focus on our product candidate ONCR-021, with plans to submit an investigation new drug application to the U.S. Food and Drug
8-K
ONCR
Oncorus, Inc.
30 Nov 22
Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer
7:07am
an investigation new drug application ("IND") to the U.S. Food and Drug Administration in mid-2023 to evaluate ONCR-021 in patients with non-small cell
8-K
EX-10.1
ONCR
Oncorus, Inc.
5 Apr 22
Entry into a Material Definitive Agreement
7:10am
investigation, of any Responsible Officer of such Person.
2. LOAN AND TERMS OF PAYMENT
2.1 Promise to Pay. Each Borrower hereby unconditionally … an investigation or review of (i) any Loan Party’s or any of its Subsidiary’s manufacturing facilities and processes for such Product which have disclosed any
8-K
EX-99.1
ue9zw eky8cg3og0
10 Jan 22
Regulation FD Disclosure
8:17am
8-K
EX-10.1
8vkayfo5tqqrvp5dj
19 Nov 21
Entry into a Material Definitive Agreement
4:47pm
8-K
EX-99.1
bef03lbog jockm93
12 Nov 21
Entry into a Material Definitive Agreement
7:45am
S-3
EX-4.6
4tlwdh w2
3 Nov 21
Shelf registration
5:00pm
10-K
ui8hymj4rnf9x4v 7q
10 Mar 21
Annual report
4:12pm
424B4
4hs npowcng9h2
12 Feb 21
Prospectus supplement with pricing info
4:23pm
DRS
EX-10.21
93eu43h28p0ndmw7ta3f
28 Jan 21
Draft registration statement
12:00am
DRS
neczshr
28 Jan 21
Draft registration statement
12:00am
10-Q
6gv1a4dwpem 3ml
12 Nov 20
Quarterly report
8:01am
8-K
EX-3.2
0qrbu56v9omlop nok5t
6 Oct 20
Amendments to Articles of Incorporation or Bylaws
4:37pm
424B4
yselrgi
2 Oct 20
Prospectus supplement with pricing info
12:00am